(Q33404428)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23161409%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

title

Phase II study of cisplatin and oral VP16 in patients with refractory or relapsed Ewing sarcoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23161409%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

1 reference

Anne-Sophie Defachelles

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23161409%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

Hervé J. Brisse

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23161409%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

author name string

Cormac Owens

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23161409%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

Valerie Laurence

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23161409%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

Lofti Benboubker

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23161409%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

Didier Cupissol

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23161409%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

Hervé Rubie

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23161409%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

Annie Rey

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23161409%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

Liliane Ollivier

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23161409%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

Dominique Couanet

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23161409%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

Christiane Baunin

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23161409%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

Céline Mahier Aït-Oukhatar

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23161409%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

Odile Oberlin

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23161409%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

publication date

17 November 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23161409%20AND%20SRC:MED&resulttype=core&format=json

Cancer Chemotherapy and Pharmacology

18 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23161409%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

volume

71

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23161409%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23161409%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

page(s)

399-404

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23161409%20AND%20SRC:MED&resulttype=core&format=json

Long-term event-free survival after intensive chemotherapy for Ewing's family of tumors in children and young adults.

18 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2015-7

Results of the EICESS-92 Study: two randomized trials of Ewing's sarcoma treatment--cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2015-7

Treatment of Ewing sarcoma family of tumors: current status and outlook for the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2015-7

Prognostic factors in Ewing's tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2015-7

Survival after recurrence of Ewing's sarcoma family of tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2015-7

Outcome after relapse in an unselected cohort of children and adolescents with Ewing sarcoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2015-7

Insulin-like growth factor-I-dependent growth and in vitro chemosensitivity of Ewing's sarcoma and peripheral primitive neuroectodermal tumour cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2015-7

Relationship between the exposure to cisplatin, DNA-adduct formation in leucocytes and tumour response in patients with solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2015-7

Phase II study of weekly high-dose cisplatin for six cycles in patients with locally advanced squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2015-7

Phase II study of a short course of weekly high-dose cisplatin combined with long-term oral etoposide in pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2015-7

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2015-7

Reporting results of cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2015-7

Optimal two-stage designs for phase II clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2015-7

Phase II study of 21 day schedule oral etoposide in children. New Agents Group of the United Kingdom Children's Cancer Study Group (UKCCSG).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2015-7

Prolonged administration of infusional cisplatin and oral etoposide in advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2015-7

Drugs five years later. Cisplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2015-7

Assessment of chemotherapy-associated nephrotoxicity in children with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2015-7

Hearing loss in children receiving cisplatin chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2015-7

Cisplatin ototoxicity in children: a practical grading system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2015-7

Topotecan and cyclophosphamide in patients with refractory or relapsed Ewing tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2015-7

Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2015-7

Irinotecan and temozolomide for Ewing sarcoma: the Memorial Sloan-Kettering experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2015-7

Phase II study of sequential gemcitabine followed by docetaxel for recurrent Ewing sarcoma, osteosarcoma, or unresectable or locally recurrent chondrosarcoma: results of Sarcoma Alliance for Research Through Collaboration Study 003.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2015-7